AMS scores decrease over three days at high-altitude. حسب Erica C. Heinrich (6832055)

MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG. حسب Rodrigo Ibarra-García-Padilla (19697623)

Image_2_No Evidence for a Decrease in Physical Activity Among Swiss Office Workers During COVID-19: A Longitudinal Study.TIFF حسب Andrea Martina Aegerter (10127111)

"…</p>Methods<p>Office workers from two Swiss organizations, aged 18–65 years, were included. …"

GSK343 decreased viability and proliferation in human neuroblastoma PDX cells. حسب Laura V. Bownes (10276762)

"…Treatment with GSK343 resulted in significantly decreased migration. (D) After 24 hours of treatment with increasing concentrations of GSK343 (0, 5, 10 μM), COA3 and COA6 cells (4.0 × 10⁴) were plated in Transwell^® inserts and allowed to invade for 1 week through a Matrigel^™ layer. …"

LCN2 treatment decreases the extent of hippocampal LTP in brain slices. حسب Jae-Hong Kim (124622)

NSC population and proliferation decrease drastically during the second postnatal week of DG development. حسب Cristina Medina-Menéndez (21800157)

Table5_Effects of exercise modalities on decreased blood pressure in patients with hypertension.docx حسب Thiago Rozales Ramis (5311217)

The decrease or inhibition of Hsp90 induced REST degradation. حسب Raúl Orozco-Díaz (7067624)

"…<p>(A) Effect of Hsp90α ASO on cell viability. Differentiated SH-SY5Y cells were transfected with different concentrations of Hsp90α ASO. …"

CcnA mutation of Loop A decreases the interaction with the 5′ UTR of P2-<i>ctrA</i> mRNA and 5′ UTR of <i>gcrA</i> mRNA. حسب Wanassa Beroual (5314028)

Decreased production of antiviral factors in patients infected with SARS-CoV-2 due to reduced TLR7 expression حسب Julia Cataldo Lima (22811497)

"…<p>The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic presents a major global health challenge. …"

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات: